Patent intelligence · US
US 12168688
Antibodies and variants thereof against PD-L1
Antibodies and variants thereof against PD-L1
Patent details — US 12168688
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 17, 2024
- Expiration
- Dec 12, 2044
- Applicant
- Nanjing Legend Biotech Co., Ltd
- Claims
- 21
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00
Quick answer
US 12168688 (Antibodies and variants thereof against PD-L1) is held by Nanjing Legend Biotech Co., Ltd. Status: granted. Granted Dec 17, 2024. Expires Dec 12, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Nanjing Legend Biotech Co., Ltd
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00
More from Nanjing Legend Biotech Co., Ltd
Related pharmaceutical patents in our USPTO index.
-
US 12421292
Anti-DLL3 chimeric antigen receptors and uses thereof
granted -
US 12351638
Chimeric antigen receptors targeting BCMA and methods of use thereof
granted -
US 12275788
Single-domain antibodies against CD33 and constructs thereof
granted -
US 12258418
Claudin18.2 binding moieties and uses thereof
granted -
US 12240914
Antibody against factor XIa in activated form of coagulant factor XI, preparation method therefor and use thereof
granted -
US 12097219
Single-domain antibodies against CLL1 and constructs thereof
granted -
US 12006363
Anti-tetraspanin 33 agents and compositions and methods for making and using the same
granted
Frequently asked questions
What is US patent 12168688?
US 12168688 (Antibodies and variants thereof against PD-L1) is held by Nanjing Legend Biotech Co., Ltd. Status: granted. Granted Dec 17, 2024. Expires Dec 12, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12168688?
Nanjing Legend Biotech Co., Ltd is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.
When does US 12168688 expire?
Our index shows an expiration date of Dec 12, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.